TY - JOUR AU - Brady, R. O. AU - Gal, A. E. AU - Bradley, R. M. AU - Martensson, E. AU - Warshaw, A. L. AU - Laster, L. PY - 1967 DA - 1967// TI - Enzymatic Defect in Fabry's Disease JO - New England Journal of Medicine VL - 276 UR - https://doi.org/10.1056/NEJM196705252762101 DO - 10.1056/NEJM196705252762101 ID - Brady1967 ER - TY - CHAP AU - Desnick, R. J. AU - Ioannou, Y. A. AU - Eng, M. E. ED - Scriver, C. R. ED - Beaudet, A. L. ED - Sly, W. S. ED - Valle, D. PY - 2001 DA - 2001// TI - Alpha-galactosidase A deficiency: Fabry disease BT - The metabolic and molecular bases of inherited disease PB - McGraw-Hill CY - New York ID - Desnick2001 ER - TY - JOUR AU - Schiffmann, R. AU - Kopp, J. B. AU - Austin, H. A. AU - Sabnis, S. AU - Moore, D. F. AU - Weibel, T. PY - 2001 DA - 2001// TI - Enzyme replacement therapy in Fabry disease: a randomized controlled trial JO - JAMA VL - 285 UR - https://doi.org/10.1001/jama.285.21.2743 DO - 10.1001/jama.285.21.2743 ID - Schiffmann2001 ER - TY - JOUR AU - Baehner, F. AU - Kampmann, C. AU - Whybra, C. AU - Miebach, E. AU - Wiethoff, C. M. AU - Beck, M. PY - 2003 DA - 2003// TI - Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study JO - J Inherit Metab Dis VL - 26 UR - https://doi.org/10.1023/B:BOLI.0000005658.14563.77 DO - 10.1023/B:BOLI.0000005658.14563.77 ID - Baehner2003 ER - TY - JOUR AU - Schiffmann, R. AU - Ries, M. AU - Timmons, M. AU - Flaherty, J. T. AU - Brady, R. O. PY - 2006 DA - 2006// TI - Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting JO - Nephrol Dial Transplant VL - 21 UR - https://doi.org/10.1093/ndt/gfi152 DO - 10.1093/ndt/gfi152 ID - Schiffmann2006 ER - TY - JOUR AU - Eng, C. M. AU - Guffon, N. AU - Wilcox, W. R. AU - Germain, D. P. AU - Lee, P. AU - Waldek, S. PY - 2001 DA - 2001// TI - Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease JO - N Engl J Med VL - 345 UR - https://doi.org/10.1056/NEJM200107053450102 DO - 10.1056/NEJM200107053450102 ID - Eng2001 ER - TY - JOUR AU - Weidemann, F. AU - Breunig, F. AU - Beer, M. AU - Sandstede, J. AU - Turschner, O. AU - Voelker, W. PY - 2003 DA - 2003// TI - Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study JO - Circulation VL - 108 UR - https://doi.org/10.1161/01.CIR.0000091253.71282.04 DO - 10.1161/01.CIR.0000091253.71282.04 ID - Weidemann2003 ER - TY - JOUR AU - Wilcox, W. R. AU - Banikazemi, M. AU - Guffon, N. AU - Waldek, S. AU - Lee, P. AU - Linthorst, G. E. PY - 2004 DA - 2004// TI - Long-term safety and efficacy of enzyme replacement therapy for Fabry disease JO - Am J Hum Genet VL - 75 UR - https://doi.org/10.1086/422366 DO - 10.1086/422366 ID - Wilcox2004 ER - TY - JOUR AU - Banikazemi, M. AU - Bultas, J. AU - Waldek, S. AU - Wilcox, W. R. AU - Whitley, C. B. AU - McDonald, M. PY - 2007 DA - 2007// TI - Agalsidase-beta therapy for advanced Fabry disease: a randomized trial JO - Ann Intern Med VL - 146 UR - https://doi.org/10.7326/0003-4819-146-2-200701160-00148 DO - 10.7326/0003-4819-146-2-200701160-00148 ID - Banikazemi2007 ER - TY - JOUR AU - Breunig, F. AU - Weidemann, F. AU - Strotmann, J. AU - Knoll, A. AU - Wanner, C. PY - 2006 DA - 2006// TI - Clinical benefit of enzyme replacement therapy in Fabry disease JO - Kidney Int VL - 69 UR - https://doi.org/10.1038/sj.ki.5000208 DO - 10.1038/sj.ki.5000208 ID - Breunig2006 ER - TY - JOUR AU - Vedder, A. C. AU - Linthorst, G. E. AU - Houge, G. AU - Groener, J. E. AU - Ormel, E. E. AU - Bouma, B. J. PY - 2007 DA - 2007// TI - Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg JO - PLoS One VL - 2 UR - https://doi.org/10.1371/journal.pone.0000598 DO - 10.1371/journal.pone.0000598 ID - Vedder2007 ER - TY - STD TI - Press release EMA 25 june 2009. [http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500008334.pdf]. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500008334.pdf ID - ref12 ER - TY - BOOK PY - 2010 DA - 2010// TI - European Medicines Agency gives new temporary treatment recommendations for Fabrazyme ID - ref13 ER - TY - BOOK PY - 2010 DA - 2010// TI - Overview of shortage Period: Spontaneous Reports from June 2009 through 15 September 2010 and Registry data from June 2009 through 05 August ID - ref14 ER - TY - JOUR AU - Levey, A. S. AU - Coresh, J. AU - Greene, T. AU - Stevens, L. A. AU - Zhang, Y. L. AU - Hendriksen, S. PY - 2006 DA - 2006// TI - Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate JO - Ann Intern Med VL - 145 UR - https://doi.org/10.7326/0003-4819-145-4-200608150-00004 DO - 10.7326/0003-4819-145-4-200608150-00004 ID - Levey2006 ER - TY - JOUR AU - Rombach, S. M. AU - Baas, M. C. AU - Ten Berge, I. J. AU - Krediet, R. T. AU - Bemelman, F. J. AU - Hollak, C. E. PY - 2010 DA - 2010// TI - The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease JO - Nephrol Dial Transplant VL - 8 ID - Rombach2010 ER - TY - JOUR AU - Devereux, R. B. PY - 1987 DA - 1987// TI - Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods JO - Hypertension VL - 9 ID - Devereux1987 ER - TY - BOOK AU - Ware, J. AU - Snow, K. AU - Kosinki, M. AU - Gandek, B. PY - 1997 DA - 1997// TI - SF36 Health Survey: manual and interpretation guide ID - Ware1997 ER - TY - JOUR AU - Simon, G. E. AU - Revicki, D. A. AU - Grothaus, L. AU - Vonkorff, M. PY - 1998 DA - 1998// TI - SF-36 summary scores: are physical and mental health truly distinct? JO - Med Care VL - 36 UR - https://doi.org/10.1097/00005650-199804000-00012 DO - 10.1097/00005650-199804000-00012 ID - Simon1998 ER - TY - JOUR AU - Ware, J. AU - Kosinski, M. PY - 2001 DA - 2001// TI - Interpreting SF&-36 summary health measures: A response JO - Quality of Life Research VL - 10 UR - https://doi.org/10.1023/A:1012588218728 DO - 10.1023/A:1012588218728 ID - Ware2001 ER - TY - JOUR AU - Bjorner, J. B. AU - Wallenstein, G. V. AU - Martin, M. C. AU - Lin, P. AU - Blaisdell-Gross, B. AU - Tak Piech, C. PY - 2007 DA - 2007// TI - Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference JO - Curr Med Res Opin VL - 23 UR - https://doi.org/10.1185/030079907X178757 DO - 10.1185/030079907X178757 ID - Bjorner2007 ER - TY - JOUR AU - Kosinski, M. AU - Zhao, S. Z. AU - Dedhiya, S. AU - Osterhaus, J. T. AU - Ware, J. E. PY - 2000 DA - 2000// TI - Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis JO - Arthritis & Rheumatism VL - 43 UR - https://doi.org/3.0.CO;2-M DO - 3.0.CO;2-M ID - Kosinski2000 ER - TY - JOUR AU - Swigris, J. J. AU - Brown, K. K. AU - Behr, J. AU - du Bois, R. M. AU - King, T. E. AU - Raghu, G. PY - 2010 DA - 2010// TI - The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF JO - Respiratory Medicine VL - 104 UR - https://doi.org/10.1016/j.rmed.2009.09.006 DO - 10.1016/j.rmed.2009.09.006 ID - Swigris2010 ER - TY - JOUR AU - van Breemen, M. J. AU - Rombach, S. M. AU - Dekker, N. AU - Poorthuis, B. J. AU - Linthorst, G. E. AU - Zwinderman, A. H. PY - 2011 DA - 2011// TI - Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy JO - Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease VL - 1812 UR - https://doi.org/10.1016/j.bbadis.2010.09.007 DO - 10.1016/j.bbadis.2010.09.007 ID - van Breemen2011 ER - TY - JOUR AU - Beck, M. PY - 2006 DA - 2006// TI - The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease JO - Acta Paediatr Suppl VL - 95 UR - https://doi.org/10.1080/08035320600618825 DO - 10.1080/08035320600618825 ID - Beck2006 ER - TY - JOUR AU - Wang, R. Y. AU - Lelis, A. AU - Mirocha, J. AU - Wilcox, W. R. PY - 2007 DA - 2007// TI - Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life JO - Genet Med VL - 9 UR - https://doi.org/10.1097/GIM.0b013e31802d8321 DO - 10.1097/GIM.0b013e31802d8321 ID - Wang2007 ER - TY - JOUR AU - Gold, K. F. AU - Pastores, G. M. AU - Botteman, M. F. AU - Yeh, J. M. AU - Sweeney, S. AU - Aliski, W. PY - 2002 DA - 2002// TI - Quality of life of patients with Fabry disease JO - Qual Life Res VL - 11 UR - https://doi.org/10.1023/A:1015511908710 DO - 10.1023/A:1015511908710 ID - Gold2002 ER - TY - JOUR AU - Aerts, J. M. AU - Groener, J. E. AU - Kuiper, S. AU - Donker-Koopman, W. E. AU - Strijland, A. AU - Ottenhoff, R. PY - 2008 DA - 2008// TI - Elevated globotriaosylsphingosine is a hallmark of Fabry disease JO - Proc Natl Acad Sci USA VL - 105 UR - https://doi.org/10.1073/pnas.0712309105 DO - 10.1073/pnas.0712309105 ID - Aerts2008 ER - TY - JOUR AU - Rombach, S. M. AU - Dekker, N. AU - Bouwman, M. G. AU - Linthorst, G. E. AU - Zwinderman, A. H. AU - Wijburg, F. A. PY - 2010 DA - 2010// TI - Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease JO - Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease VL - 1802 UR - https://doi.org/10.1016/j.bbadis.2010.05.003 DO - 10.1016/j.bbadis.2010.05.003 ID - Rombach2010 ER - TY - JOUR AU - Benichou, B. AU - Goyal, S. AU - Sung, C. AU - Norfleet, A. M. AU - O'Brien, F. PY - 2009 DA - 2009// TI - A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease JO - Mol Genet Metab VL - 96 UR - https://doi.org/10.1016/j.ymgme.2008.10.004 DO - 10.1016/j.ymgme.2008.10.004 ID - Benichou2009 ER - TY - JOUR AU - Linthorst, G. E. AU - Hollak, C. E. AU - Donker-Koopman, W. E. AU - Strijland, A. AU - Aerts, J. M. PY - 2004 DA - 2004// TI - Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta JO - Kidney Int VL - 66 UR - https://doi.org/10.1111/j.1523-1755.2004.00924.x DO - 10.1111/j.1523-1755.2004.00924.x ID - Linthorst2004 ER - TY - JOUR AU - Fost, d. M. AU - Hollak, C. E. AU - Groener, J. E. AU - Aerts, J. M. AU - Maas, M. AU - Poll, L. W. PY - 2006 DA - 2006// TI - Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2005-12-5072 DO - 10.1182/blood-2005-12-5072 ID - Fost2006 ER - TY - JOUR AU - Hollak, C. E. M. PY - 2011 DA - 2011// TI - Short-term withdrawal from imiglucerase: What can we learn from it? JO - Blood Cells, Molecules, and Diseases VL - 46 UR - https://doi.org/10.1016/j.bcmd.2010.05.003 DO - 10.1016/j.bcmd.2010.05.003 ID - Hollak2011 ER - TY - JOUR AU - Goldblatt, J. AU - Fletcher, J. M. AU - McGill, J. AU - Szer, J. AU - Wilson, M. PY - 2011 DA - 2011// TI - Enzyme replacement therapy "drug holiday": Results from an unexpected shortage of an orphan drug supply in Australia JO - Blood Cells, Molecules, and Diseases VL - 46 UR - https://doi.org/10.1016/j.bcmd.2010.05.002 DO - 10.1016/j.bcmd.2010.05.002 ID - Goldblatt2011 ER - TY - JOUR AU - Zimran, A. AU - Altarescu, G. AU - Elstein, D. PY - 2011 DA - 2011// TI - Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply JO - Blood Cells, Molecules, and Diseases VL - 46 UR - https://doi.org/10.1016/j.bcmd.2010.05.001 DO - 10.1016/j.bcmd.2010.05.001 ID - Zimran2011 ER -